ArticleRespiratory research2026
The GAP43/RAC1 axis drives glycolytic reprogramming and progression in lung adenocarcinoma.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer (NSCLC) and poses a significant threat to public health. Traditional treatments often lead to poor prognoses and tumor recurrence. Glycolysis plays a crucial role in the initiation and progression of LUAD, making it an important area of research for the development of new therapeutic strategies.
methodsIn this study, we analyzed the Cancer Genome Atlas (TCGA) data to assess GAP43 expression and prognostic value in LUAD. Functional roles were investigated using GAP43 knockdown and overexpression cell lines through proliferation, apoptosis, colony formation, wound healing, and Transwell assays. The nude mouse xenograft tumor model was used to validate the effects of GAP43 knockdown on tumor growth in vivo. RAC1 was identified as a downstream target via gene set enrichment analysis (GSEA) and correlation analysis. Glycolytic activity (glucose uptake, ATP/lactate production, OCR/ECAR) and related protein expression were measured, and GAP43-RAC1 interaction was examined by co-immunoprecipitation.
resultsGAP43 expression was significantly upregulated in LUAD tissues compared with normal tissues and that high GAP43 expression was associated with poor overall survival (OS) and progression-free survival (PFS). GAP43 knockdown significantly inhibited the proliferation, migration, and invasive capabilities of LUAD cells in vitro and suppressed tumor growth in vivo. Conversely, its overexpression promoted malignant behavior of tumor cells. Mechanistically, GAP43 promoted the transcription of RAC1 by binding to the transcription factor CREB1, thereby enhancing aerobic glycolysis and facilitating the malignant progression of LUAD.
conclusionsThe results of this study suggest that GAP43 may serve as a potential therapeutic target for LUAD. The GAP43/RAC1 axis plays a crucial role in regulating glycolysis and malignant phenotypes in LUAD cells, offering new insights for the clinical management of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.